Literature DB >> 18611063

A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.

Felix Bronner1, Boris M Slepchenko, Michael Pennick, Stephen J P Damment.   

Abstract

OBJECTIVE: Lanthanum carbonate (Fosrenol) is a non-calcium phosphate binder that controls hyperphosphataemia without increasing calcium intake above guideline targets. The biological fate and bone load of lanthanum were modelled with the aid of a four-compartment kinetic model, analogous to that of calcium.
METHODS: The model used data from healthy subjects who received intravenous lanthanum chloride or oral lanthanum carbonate, and bone lanthanum concentration data collected from dialysis patients during three long-term trials (up to 5 years).
RESULTS: Infusion of lanthanum chloride or ingestion of lanthanum carbonate led to a rapid rise in plasma lanthanum concentrations, followed by an exponential decrease. Comparison of oral and intravenous exposure confirmed that lanthanum is very poorly absorbed. On a typical intake of lanthanum (3000 mg/day as lanthanum carbonate), the rate of absorption was calculated as 2.2 microg/h, with a urinary excretion rate constant of 0.004-0.01 h(-1). The faecal content of endogenous lanthanum was estimated to be 8- to 20-fold greater than that of urine, compared with a ratio of only about 1 for calcium. The model predicts that upon multiple dosing, plasma lanthanum concentrations rise rapidly to a near plateau and then increase by about 3% per year. However, this small change is obscured by the variability of the study data, which show that a plateau is rapidly attained by 2 weeks and is thereafter maintained for at least 2 years. The initial deposition rate of lanthanum in bone was 1 microg/g/year and, after 10 years of lanthanum carbonate treatment, the model predicts a 7-fold increase in total bone lanthanum (from 10 mg to 69 mg [from 1 microg/g wet weight to 6.6 microg/g wet weight]), with lanthanum cleared after cessation of treatment at 13% per year. The model indicates that lanthanum flow from bone surface to bone interior is much lower than that of calcium.
CONCLUSION: Bone is the major reservoir for metals, but bone lanthanum concentrations are predicted to remain low after long-term treatment because of very poor intestinal absorption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18611063     DOI: 10.2165/00003088-200847080-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  37 in total

1.  Quantitation of calcium metabolism. Theory.

Authors:  J P AUBERT; F BRONNER; L J RICHELLE
Journal:  J Clin Invest       Date:  1963-06       Impact factor: 14.808

2.  Enlightenment on liver lanthanum exposure.

Authors:  S J P Damment
Journal:  Kidney Int       Date:  2006-10       Impact factor: 10.612

3.  The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.

Authors:  A J Freemont; J A Hoyland; J Denton
Journal:  Clin Nephrol       Date:  2005-12       Impact factor: 0.975

4.  Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease.

Authors:  S Mathew; M Davies; R Lund; G Saab; K A Hruska
Journal:  Eur J Clin Invest       Date:  2006-08       Impact factor: 4.686

5.  Human metabolism of aluminium-26 and gallium-67 injected as citrates.

Authors:  N D Priest; D Newton; J P Day; R J Talbot; A J Warner
Journal:  Hum Exp Toxicol       Date:  1995-03       Impact factor: 2.903

Review 6.  Osteogenic regulation of vascular calcification: an early perspective.

Authors:  Radhika Vattikuti; Dwight A Towler
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-05       Impact factor: 4.310

Review 7.  Slowing the progression of vascular calcification in hemodialysis.

Authors:  Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

Review 8.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.

Authors:  E Slatopolsky; C Weerts; S Lopez-Hilker; K Norwood; M Zink; D Windus; J Delmez
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

Review 10.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more
  7 in total

Review 1.  Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Authors:  Stephen J P Damment; Michael Pennick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 2.  Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

3.  Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.

Authors:  Stephen Damment; Roger Secker; Victor Shen; Victor Lorenzo; Mariano Rodriguez
Journal:  Nephrol Dial Transplant       Date:  2010-11-22       Impact factor: 5.992

4.  Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.

Authors:  Veerle P Persy; Geert J Behets; Marc E De Broe; Patrick C D'Haese
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-04-01

Review 5.  Lanthanum carbonate: safety data after 10 years.

Authors:  Alastair J Hutchison; Rosamund J Wilson; Svetlana Garafola; John Brian Copley
Journal:  Nephrology (Carlton)       Date:  2016-12       Impact factor: 2.506

6.  PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.

Authors:  Atsushi Yaguchi; Satoshi Tatemichi; Hiroo Takeda; Mamoru Kobayashi
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

7.  Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis.

Authors:  Yunyun Di; Ellen K Wasan; Jacqueline Cawthray; Jaweria Syeda; Munawar Ali; David M L Cooper; Ahmad Al-Dissi; Nima Ashjaee; Wubin Cheng; James Johnston; David M Weekes; Thomas I Kostelnik; Chris Orvig; Kishor M Wasan
Journal:  Bone Rep       Date:  2021-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.